Skip to main content

Mini-Sentinel: Summary of Antidiabetic Agent Use During Pregnancy

    Basic Details
    Date Posted
    Medical Product
    alpha-glucosidase inhibitor
    amylin analog
    dipeptidyl peptidase-4 (DPP-4) inhibitor
    glucagon-like peptide-1 (GLP-1) receptor agonists
    injectable insulin
    meglitinide analog
    Health Outcome(s)
    exposure in pregnancy

    This report contains estimates of the prevalence of antidiabetic agent use among females 10 to 54 years of age who delivered a live-born infant between January 1, 2001 and December 31, 2013 in the Mini-Sentinel Distributed Database (MSDD). Results for antidiabetic agent use are also presented for a matched comparator cohort with no live-birth deliveries during the request period.

    Data from January 1, 2001 to December 31, 2013, from 15 Data Partners contributing to the MSDD were included in this report. This request was distributed to Data Partners on May 14, 2015.

    Additional Details
    FDA Center
    Time Period
    January 1, 2001 - December 31, 2013
    Analysis Type
    Custom Code
    Population / Cohort
    Females 10 to 54 years of age
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)